Comment on "Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial"

被引:0
|
作者
Ferreira, Daniel
机构
关键词
EARLY DISCHARGE; SEVERITY INDEX;
D O I
10.1016/j.repc.2012.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although practice guidelines recommend outpatient care for selected, haemodynamically stable patients with pulmonary embolism, most treatment is presently inpatient based. We aimed to assess non-inferiority of outpatient care compared with inpatient care. Methods: We undertook an open-label, randomised non-inferiority trial at 19 emergency departments in Switzerland, France, Belgium, and the USA. We randomly assigned patients with acute, symptomatic pulmonary embolism and a low risk of death (pulmonary embolism severity index risk classes I or II) with a computer-generated randomisation sequence (blocks of 2-4) in a 1:1 ratio to initial outpatient (ie, discharged from hospital <= 24 h after randomisation) or inpatient treatment with subcutaneous enoxaparin (>= 5 days) followed by oral anticoagulation (>= 90 days). The primary outcome was symptomatic, recurrent venous thromboembolism within 90 days; safety outcomes included major bleeding within 14 or 90 days and mortality within 90 days. We used a non-inferiority margin of 4% for a difference between inpatient and outpatient groups. We included all enrolled patients in the primary analysis, excluding those lost to follow-up. This trial is registered with ClinicalTrials.gov, number NCT00425542. Findings: Between February, 2007, and June, 2010, we enrolled 344 eligible patients. In the primary analysis, one (0.6%) of 171 outpatients developed recurrent venous thromboembolism within 90 days compared with none of 168 inpatients (95% upper confidence limit [UCL] 2.7%; p = 0.011). Only one (0.6%) patient in each treatment group died within 90 days (95% UCL 2.1%; p = 0.005), and two (1.2%) of 171 outpatients and no inpatients had major bleeding within 14 days (95% UCL 3.6%; p = 0.031). By 90 days, three (1.8%) outpatients but no inpatients had developed major bleeding (95% UCL 4.5%; p = 0.086). Mean length of stay was 0.5 days (SD 1.0) for outpatients and 3.9 days (SD 3.1) for inpatients. Interpretation: In selected low-risk patients with pulmonary embolism, outpatient care can safely and effectively be used in place of inpatient care.
引用
收藏
页码:263 / 264
页数:2
相关论文
共 50 条
  • [31] Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation:: a randomised, open-label, non-inferiority trial
    Bousser, M. G.
    Bouthier, J.
    Buller, H. R.
    Cohen, A. T.
    Crijns, H.
    Davidson, B. L.
    Halperin, J.
    Hankey, G.
    Levy, S.
    Pengo, V.
    Prandoni, P.
    Prins, M. H.
    Tomkowski, W.
    Thorp-Pedersen, C.
    Wyse, D. G.
    LANCET, 2008, 371 (9609): : 315 - 321
  • [32] Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial
    Schilsky, Michael L.
    Czlonkowska, Anna
    Zuin, Massimo
    Cassiman, David
    Twardowschy, Carlos
    Poujois, Aurelia
    Gondim, Francisco De Assis A.
    Denk, Gerald
    Cury, Rubens G.
    Ott, Peter
    Moore, Joanna
    Ala, Aftab
    D'Inca, Renata
    Couchonnal-Bedoya, Eduardo
    D'Hollander, Koenraad
    Dubois, Nicolas
    Kamlin, C. Omar F.
    Weiss, Karl Heinz
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (12): : 1092 - 1102
  • [33] Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
    Mateos, Maria-Victoria
    Nahi, Hareth
    Legiec, Wojciech
    Grosicki, Sebastian
    Vorobyev, Vladimir
    Spicka, Ivan
    Hungria, Vania
    Korenkova, Sibirina
    Bahlis, Nizar
    Flogegard, Max
    Blade, Joan
    Moreau, Philippe
    Kaiser, Martin
    Iida, Shinsuke
    Laubach, Jacob
    Magen, Hila
    Cavo, Michele
    Hulin, Cyrille
    White, Darrell
    De Stefano, Valerio
    Clemens, Pamela L.
    Masterson, Tara
    Lantz, Kristen
    O'Rourke, Lisa
    Heuck, Christoph
    Qin, Xiang
    Parasrampuria, Dolly A.
    Yuan, Zhilong
    Xu, Steven
    Qi, Ming
    Usmani, Saad Z.
    LANCET HAEMATOLOGY, 2020, 7 (05): : E370 - E380
  • [34] 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial
    de Wijkerslooth, Elisabeth M. L.
    Boerma, Evert-Jan G.
    van Rossem, Charles C.
    van Rosmalen, Joost
    Baeten, Coen I. M.
    Beverdam, Frederique H.
    Bosmans, Johanna W. A. M.
    Consten, Esther C. J.
    Dekker, Jan Willem T.
    Emous, Marloes
    van Geloven, Anna A. W.
    Gijsen, Anton F.
    Heijnen, Luc A.
    Jairam, An P.
    Melles, Damian C.
    van der Ploeg, Augustinus P. T.
    Steenvoorde, Pascal
    Toorevliet, Boudewijn R.
    Vermaas, Maarten
    Wiering, Bas
    Wijnhoven, Bas P. L.
    van den Boom, Anne Loes
    LANCET, 2023, 401 (10374): : 366 - 376
  • [35] Early versus differed arterial catheterisation in critically ill patients with acute circulatory failure: a multicentre, open-label, pragmatic, randomised, non-inferiority controlled trial: the EVERDAC protocol
    Muller, Gregoire
    Kamel, Toufik
    Contou, Damien
    Ehrmann, Stephan
    Martin, Maelle
    Quenot, Jean-Pierre
    Lacherade, Jean-Claude
    Boissier, Florence
    Monnier, Alexandra
    Vimeux, Sylvie
    Houdard, Solene Brunet
    Tavernier, Elsa
    Boulain, Thierry
    BMJ OPEN, 2021, 11 (09):
  • [36] Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
    Parekh, Dipen J.
    Reis, Isildinha M.
    Castle, Erik P.
    Gonzalgo, Mark L.
    Woods, Michael E.
    Svatek, Robert S.
    Weizer, Alon Z.
    Konety, Badrinath R.
    Tollefson, Mathew
    Krupski, Tracey L.
    Smith, Norm D.
    Shabsigh, Ahmad
    Barocas, Daniel A.
    Quek, Marcus L.
    Dash, Atreya
    Kibel, Adam S.
    Shemanski, Lynn
    Pruthi, Raj S.
    Montgomery, Jeffrey Scott
    Weight, Christopher J.
    Sharp, David S.
    Chang, Sam S.
    Cookson, Michael S.
    Gupta, Gopal N.
    Gorbonos, Alex
    Uchio, Edward M.
    Skinner, Eila
    Venkatramani, Vivek
    Soodana-Prakash, Nachiketh
    Kendrick, Kerri
    Smith, Joseph A., Jr.
    Thompson, Ian M.
    LANCET, 2018, 391 (10139): : 2525 - 2536
  • [37] Comment on Miki et al.: Randomized open-label non-inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain Reply
    Miki, Kenji
    Ikemoto, Tatsunori
    Hayashi, Kazuhiro
    Arai, Young-Chang
    Sekiguchi, Miho
    Shi, Kenrin
    Ushida, Takahiro
    JOURNAL OF ORTHOPAEDIC SCIENCE, 2019, 24 (01) : 190 - 191
  • [38] Re: Ciprofloxacin for 7 Days Versus 14 Days in Women with Acute Pyelonephritis: A Randomised, Open-Label and Double-Blind, Placebo-Controlled, Non-Inferiority Trial Editorial Comment
    Schaeffer, Edward M.
    JOURNAL OF UROLOGY, 2013, 189 (02): : 559 - 560
  • [39] Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial
    Gimbel, Marieke
    Qaderdan, Khalid
    Willemsen, Laura
    Hermanides, Rik
    Bergmeijer, Thomas
    de Vrey, Evelyn
    Heestermans, Ton
    Gin, Melvyn Tjon Joe
    Waalewijn, Reinier
    Hofma, Sjoerd
    den Hartog, Frank
    Jukema, Wouter
    von Birgelen, Clemens
    Voskuil, Michiel
    Kelder, Johannes
    Deneer, Vera
    ten Berg, Jurrien
    LANCET, 2020, 395 (10233): : 1374 - 1381
  • [40] A pragmatic randomised controlled non-inferiority trial of open-door policy versus treatment as usual in urban psychiatric inpatient wards
    Indregard, A. -M. R.
    Tesli, M. S.
    Gather, J.
    Smastuen, M. C.
    Nussle, H. M.
    Vandvik, P. O.
    Kunoe, N.
    EUROPEAN PSYCHIATRY, 2024, 67 : S62 - S62